SMS Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.

Profit growth above 25%EBITDA margin expansionResults View source PDF Explain this filing

SMSPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.1%Reaction day

₹266.39

prior close

₹262.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-2.2% vs market

Pharmaceuticals peers, median of 147sector-0.1%-2.0% vs sector

On the reaction day the stock moved 2.2 pts less than Nifty Microcap 250 and 2.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.9

10m

-4.3

15m

-4.5

30m

-2.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.1+0.1-2.2-0.1-2.0

Next day

-3.0-0.2-2.8-0.2-2.9

-4.5+0.3-4.8-0.2-4.2

-6.4+0.9-7.2+0.0-6.4

-8.1+0.8-8.8+0.0-8.1

-6.5+2.2-8.7+0.6-7.2

-3.1+3.4-6.5+1.4-4.6

15d

-12.7-0.8-11.9-2.9-9.8

-10.6+2.9-13.6+0.3-10.9

-14.8+0.8-15.7-0.4-14.5

-12.3+0.0-12.4-3.2-9.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

SMS Pharmaceuticals reported strong FY25 results with standalone revenue from operations rising to Rs. 78,274.81 lakhs from Rs. 70,926.34 lakhs in FY24, a growth of about 10.4%. Net profit jumped to Rs. 6,838.12 lakhs from Rs. 4,942.49 lakhs, a 38% YoY increase, while EPS climbed to Rs. 8.07 from Rs. 5.84. Q4 standalone profit rose to Rs. 2,062.24 lakhs from Rs. 1,592.18 lakhs a year ago. The statutory auditors (Suryanarayana & Suresh) issued an unmodified (clean) opinion on both standalone and consolidated results. The board recommended a final dividend of 40% (Re. 0.40 per share) for FY25, subject to shareholder approval.

Likely market impact

Strong profit growth and an improved operating margin signal healthy business momentum, while the 40% dividend rewards shareholders. The clean audit opinion and continued capacity investment (new greenfield subsidiary and Rs. 10 Cr infusion into SMS Peptides) suggest management confidence, though debt levels have risen modestly.